收费全文 | 18283篇 |
免费 | 1127篇 |
国内免费 | 96篇 |
耳鼻咽喉 | 223篇 |
儿科学 | 336篇 |
妇产科学 | 199篇 |
基础医学 | 2381篇 |
口腔科学 | 593篇 |
临床医学 | 1207篇 |
内科学 | 4684篇 |
皮肤病学 | 509篇 |
神经病学 | 1156篇 |
特种医学 | 989篇 |
外科学 | 3037篇 |
综合类 | 80篇 |
一般理论 | 2篇 |
预防医学 | 539篇 |
眼科学 | 345篇 |
药学 | 1161篇 |
中国医学 | 28篇 |
肿瘤学 | 2037篇 |
2023年 | 162篇 |
2022年 | 120篇 |
2021年 | 547篇 |
2020年 | 317篇 |
2019年 | 406篇 |
2018年 | 515篇 |
2017年 | 448篇 |
2016年 | 508篇 |
2015年 | 509篇 |
2014年 | 654篇 |
2013年 | 694篇 |
2012年 | 1188篇 |
2011年 | 1236篇 |
2010年 | 633篇 |
2009年 | 558篇 |
2008年 | 908篇 |
2007年 | 1019篇 |
2006年 | 930篇 |
2005年 | 877篇 |
2004年 | 809篇 |
2003年 | 763篇 |
2002年 | 687篇 |
2001年 | 439篇 |
2000年 | 478篇 |
1999年 | 429篇 |
1998年 | 147篇 |
1997年 | 136篇 |
1996年 | 101篇 |
1995年 | 93篇 |
1994年 | 93篇 |
1993年 | 97篇 |
1992年 | 332篇 |
1991年 | 305篇 |
1990年 | 258篇 |
1989年 | 239篇 |
1988年 | 234篇 |
1987年 | 213篇 |
1986年 | 180篇 |
1985年 | 164篇 |
1984年 | 130篇 |
1983年 | 113篇 |
1979年 | 67篇 |
1978年 | 52篇 |
1977年 | 55篇 |
1975年 | 61篇 |
1973年 | 51篇 |
1972年 | 57篇 |
1971年 | 47篇 |
1968年 | 60篇 |
1967年 | 64篇 |
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
Purpose
Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC.Patients and methods
The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined.Results
Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively.Conclusions
The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC. 相似文献Methods: Twenty patients who underwent MPFL reconstruction for unilateral recurrent patellar dislocation (18 females and 2 males; mean age 20.8 ± 7.6 years) were examined. The peak isometric torque at 60° and 90° of knee flexion and isokinetic knee extensor strength at speeds of 60°/s and 90°/s in operated and non-operated legs were measured using a dynamometer preoperatively and 6 months, 1 year, and 2 years postoperatively. The following parameters were evaluated: (1) body weight-adjusted muscle strength, (2) improvement index (post-/preoperative value × 100) (%), and (3) extensor strength ratio (operated/non-operated value × 100) (%).
Results: The mean knee extensor strength in both operated and non-operated legs significantly increased 2 years after surgery compared with that before surgery. At 2 years postoperatively, the improvement indexes of the isometric knee extensor strength at 60° and 90° and of the isokinetic knee extensor strength at 60°/s and 90°/s were 237%, 192%, 318%, and 186%, respectively, in the operated legs and 144%, 124%, 140%, and 140%, respectively, in the non-operated legs. At 2 years postoperatively, the mean isometric knee extensor strength ratios at 60° and 90° and the isokinetic knee extensor strength ratios at 60°/s and 180°/s were 81%, 84%, 81%, and 82%, respectively.
Conclusions: Knee extensor strength was improved in most patients after MPFL reconstruction, at least compared with that before surgery, although an approximately 20% deficit against the non-operated legs remained even 2 years after surgery. 相似文献